← Back to Newsroom

Mynarix expands sterile manufacturing capacity to meet growing demand

A new sterile fill-finish line increases annual capacity and strengthens supply resilience across priority markets.

Mynarix today announced the commissioning of a new sterile fill-finish line at its Dallas manufacturing campus, expanding annual capacity for injectable products and reinforcing supply resilience for the markets it serves.

The investment adds validated aseptic processing capability alongside the company’s existing solid-oral and inhalation lines. It is designed to current good manufacturing practice and includes automated inspection and full batch traceability from raw material to release.

“Reliable supply is inseparable from reliable quality — the new line lets us meet growing demand without ever compromising the standard our name carries,” the company said.

The expansion is expected to support both the current portfolio and programs advancing through the company’s pipeline, with first commercial batches anticipated later this year.